Clinical Trials Browser

Phase 2/3 × Pathologic Complete Response × Docetaxel × Clear all

NCT01216644 2019-06-19

5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer

Phase 2/3 Completed

Gastrointestinal

Pathologic Complete Response, Stomach Neoplasms